An extensive round of critical reports and studies provides valuable insights into the activities and potentials of Bristol-Myers Squibb Company (NYSE:BMY). Despite a 0.8% loss over the previous year, several institutional investors have seen a great week recently. BMY has made significant strides in drug-price-reduction, one notable move being providing Eliquis free to Medicaid. Market analysts such as Leerink Partners maintain a Buy rating for BMY, affirming its promise as a top value stock in the long term.
The company has also made noteworthy strides in oncology, including the approval of Breyanzi by U.S FDA for adults with relapsed or refractory Marginal Zone Lymphoma (MZL). Prominent voices like Jim Cramer have expressed interest in BMY's activities. The company’s stock has shown remarkable resilience, with a recent share price rebound prompting reassessment of its valuation.
In other news, BMY has sold some of its shares while others were bought by different entities, such as the Czech National Bank and Texas Permanent School Fund Corp. The company's stock performed well even amid broader market decline, with positive analyst upgrades and dividend hikes serving as strong catalysts. Finally, BMY's decision to join a new deal will potentially lower drug prices, thereby making it an attractive proposition for investors.
Bristol-Myers Squibb BMY News Analytics from Tue, 16 Sep 2025 07:00:00 GMT to Sat, 20 Dec 2025 13:59:58 GMT - Rating 7 - Innovation 5 - Information 8 - Rumor -4
